SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

Inclusion Criteria: Histologically or cytologically confirmed advanced ovarian cancer that has failed or intolerant or not applicable to standard treatment (applicable to the dose escalation phase of stage Ib); Histologically or cytologically confirmed advanced high-grade serous ovarian cancer, platinum-resistant or platinum-refractory recurrent ovarian cancer (applicable to the dose expansion phase of stage II); There is at least one measurable lesion that meets the definition of RECIST 1.1; Voluntarily participate in clinical trials and sign informed consent; Age ≥18 years; ECOG score of 0 to 1; Predicted life expectancy ≥3 months; Adequate bone marrow, liver biochemistry, renal function, and coagulation status. Female patients who agree to use adequate contraceptive measures. Exclusion Criteria: Received chemotherapy, radiotherapy, immunotherapy or biological therapy, steroid therapy or other investigational drugs <28 days prior to the first dose of study treatment. Patients who have not fully recovered from surgery according to the investigator's judgment.; Patients who have previously received WEE1 inhibitor treatment; Unresolved AEs or toxicities due to previous treatments; Patients with contraindications or a history of severe allergies to gemcitabine or paclitaxel; Known malignant CNS disease other than neurologically stable, treated brain metastases; Other medical conditions or systemic diseases not suitable to participate; The need for long-term therapeutic doses of anticoagulant or antiplatelet drugs; Received CYP3A4 moderate or strong inhibitors or CYP3A4 moderate or strong inducers within 14 days; Pregnant or lactating women.